Gland Pharma Receives US FDA Approval for Generic Sugammadex Injection, Launches Product in U.S.
Gland Pharma Limited has strengthened its presence in the U.S. pharmaceutical market after receiving final approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection. Following the regulatory clearance, the company has commercially launched the product in the United States through its marketing partner, enabling immediate market availability.
US FDA Approves Generic Sugammadex Injection
The approval covers Sugammadex Injection in the following presentations:
- 200 mg/2 mL (100 mg/mL) single-dose vial
- 500 mg/5 mL (100 mg/mL) single-dose vial
Gland Pharma’s product has been approved as a generic equivalent to BRIDION® (Sugammadex) Injection, the reference listed drug marketed by Merck Sharp & Dohme LLC. The company stated that its formulation is both bioequivalent and therapeutically equivalent, meeting the regulatory standards required for approval.
Used to Reverse Neuromuscular Blockade
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide during surgical procedures. The medicine is used in both adult and pediatric patients to help restore normal muscle function after anesthesia, making it an important product in perioperative care.
Large U.S. Market Opportunity
The approval opens access to a significant commercial opportunity for Gland Pharma. According to IQVIA data cited by the company, Sugammadex Injection generated approximately USD 1.6 billion in annual U.S. sales during the 12-month period ending April 2026.
With an immediate commercial launch, Gland Pharma is well-positioned to compete in this high-value generic injectable market and capitalize on early demand through its established distribution and marketing network in the United States.
Strengthening the Generic Injectables Portfolio
The latest approval further expands Gland Pharma’s portfolio of complex injectable products and reinforces its strategy of increasing its presence in regulated global markets.
The company has built a strong reputation in sterile injectable manufacturing and continues to focus on developing high-value generic medicines with significant commercial potential. Early market entry is expected to support revenue growth and strengthen its position in the competitive U.S. pharmaceutical market.
About Gland Pharma Limited
Founded in 1978 and headquartered in Hyderabad, Gland Pharma Limited is one of the world’s leading manufacturers of injectable pharmaceuticals. Operating primarily under a business-to-business (B2B) model, the company supplies a wide range of sterile injectable products to more than 60 countries, including the United States, Europe, Canada, Australia, and India.
Its product portfolio includes injectable formulations such as vials, ampoules, pre-filled syringes, lyophilized products, oncology medicines, and ophthalmic solutions, making Gland Pharma a prominent player in the global generic injectables industry.